UTUC Flashcards

1
Q

What other workup needs to be done in a patient with suspected UTUC?

A
  1. cystoscopy
  2. upper tract imaging - CTU preferred. If contraindicated, next is MRU, followed by RUS w/ retrograde pyelograms
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

What are the differentials for ureteral mass?

A

UTUC, fungal ball, blood clot, radiolucent kidney stone

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

What is first step in diagnostic workup for a suspected UTUC?

A
  1. ureteroscopy w/ biopsy (retrograde vs antegrade)
  2. cytology
  3. can consider therapeutic all at once as well
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

If the ureter is tight in a patient with suspected UTUC, and it is difficult to advance retrograde, what are your options?

A
  1. Place a stent , and return in a couple weeks. You do not want to have ureteral perforations, as risk for seeding, in these patients
    - limit use of access sheaths
    - do get cytology during the procedure though
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Do you check the contralateral ureter if it looks normal on radiograph?

A

NO

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Which syndromes are you investigating in patients with UTUC?

A
  1. Lynch syndrome - colorectal, ovarian, pancreatic, prostate, biliary, etc)
  2. need referral to genetic counselor
  3. Lynch is AD
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

How do you workup potential Lynch?

A

Do IHC (immunohistological) testing with reflexive tests for mismatch repair genes as well as microsatellite instability

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

What is important to document from an endoscopic perspective?

A

tumor location, characteristics, number of tumors, tumor appearance, estimate size

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Give me the TNM grading for

A

Ta - noninvasive
Tis - CIS
T1 - subepithelial
T2 - muscle
T3 - periureteral fat, renal pelvis, or beyond renal parenchyma
T4 - perinephric fat or adjacent organ

N1 - < 2cm nodal metastasis
N2 - between 2 and 5 cm
N3 - > 5 cm nodal metastasis

M1 - distant metastasis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Provide me with characteristics for low and high risk categories

A

Low:
Favorable - low grade, papillary, unifocal, no obstruction, cytology is negative
Tx: ablation

Unfavorable - low grade, papillary, multifocal, obstruction, cytology is negative for HGUC, or has lower urinary tract involvement
Tx: may offer ablation

High:
Favorable - high grade, papillary, unifocal, no obstruction. any cytology
Tx: rarely ablation. should consider neoadjuvant vs adjuvant

Unfavorable - high grade, sessile, obstruction, any cytology, + lymph nodes, + lower urinary tract involvement, + invasion
Tx: palliation ablation only. neoadjuvant vs adjuvant

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

In a patient with obstruction, is perc or stent preferred?

A

Stent. Perc precludes to potential tract seeding

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

What are some risk facts for CKD development post NU?

A

age, DM, HTN, male, obesity, tobacco, tumor size

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

What are risks that you must discuss with patient about choosing kidney sparing?

A

Repeat need for ureteroscopy surveillance, which may lead to strictures, ureteral perforation, etc

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

What are risks of mitomycin C?

A

ureteral obstruction, bone marrow suppression

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Can mitomycin C clear residual tumor?

A

Yes - but it should not be relied upon, if endoscopic clearance can be accomplished

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

How soon to survey after endoscopic management?

17
Q

What are some agents that can be delivered post resection?

A

mitomycin C, gemcitaibine, BCG, docetaxel

18
Q

Where should these be delivered?

A

upper urinary tract, and consider bladder.
MUST MAKE SURE NO PERFORATION

19
Q

When in particular should BCG be used?

A

for high risk endoscopic removal (includes CIS)

20
Q

What is treatment for HR UTUC?

A

radical NU w/ complete bladder cuff excision with lymphadenopathy

21
Q

What are important considerations for patients undergoing a segmental ureterectomy?

A
  • must make sure to have negative margins
  • prior endoscopic assessment
22
Q

What is preferred surgery for HR or unfavorable LR UTUC in a good kidney patient, with focalized distal disease?

A

distal ureterectomy with ureteral reimplant

23
Q

What should be given after any RNU or distal ureterectomy?

A

intravesical MMC

24
Q

What are the templates for LND in HR patients?

A
  1. pyelocaliceal area - node packets in the renal hilum to IMA
  2. prox 2/3 ureter - LN from renal hilum to aortic bifurcation
  3. distal 1/3 ureter - obturator + external iliac LN
25
What is the neoadjuvant chemotherapy of choice?
MVAC
26
What is adjuvant chemotherapy of choice
Platinum-based - cisplatin or carboplatin +/- gemcitiabine
27
What are alternative adjuvants for those who have received neoadjuvant, but don't wish cisplatin either?
Nivolumab
28
What is treatment for metastatic disease (including lymph node)?
Chemotherapy. Consideration for consolidative tx if patient has improvement (partial or full)
29
What is surveillance for LR , kidney-sparing approach?
First cysto / URS - 3 months Cysto -Then every six months for first two years, followed by yearly. URS - Every six months for first year, then per imaging CTU - every six months for two years, followed by yearly After five years is dependent on patient.
30
What is surveillance for HR, kidney-sparing approach?
First cysto / URS / CYTOLOGY = 3 months Cysto/Cytology - every six months for first three years, then annually URS - every six months for first year CTU - every six months for three years, then annually SDM after five years
31
What is surveillance for LR and HR, after rNU - (< pT2)
LR - cystoscopy + cytology at 3 months, then every 6 months for two years, annually HR - cystoscopy + cytology at 3 months, then every six months for three years, annually Cross-sectional imaging, baseline within six months, then annually afterwards
32
What is surveillance for LR and HR, after rNU - (> pT2)
cystoscopy + cytology at 3 months, then every six months for three years, annually Cross-sectional imaging every six months for two years, then annually Chest CT - 6/12 months for first five years